InvestorsHub Logo
Followers 3
Posts 117
Boards Moderated 0
Alias Born 02/16/2015

Re: None

Monday, 10/23/2017 7:02:37 PM

Monday, October 23, 2017 7:02:37 PM

Post# of 289
Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
[Marketwired]
MarketwiredSeptember 26, 2017

AUSTIN, TX --(Marketwired - September 26, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin hydrochloride inhalation powder) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SVRA News